Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

January 2016 - FRMC

02/02/2016
Patients with CKD and hyperkalemia found that treatment with patiromer was associated with a reduction in serum potassium levels and a reduction in recurrence.
Patients with CKD and hyperkalemia found that treatment with patiromer was associated with a reduction in serum potassium levels and a reduction in recurrence.
Patients with CKD and...
02/02/2016
First Report Managed Care
Department
02/02/2016
The FDA approved Zurampic (lesinurad) used in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricemia associated with gout. XOI is used to reduce the production of uric acid in the body.
The FDA approved Zurampic (lesinurad) used in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricemia associated with gout. XOI is used to reduce the production of uric acid in the body.
The FDA approved Zurampic...
02/02/2016
First Report Managed Care
02/02/2016

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
With new drugs targeting second-line therapy, a crowded treatment algorithm may be on the horizon for patients with NSCLC. 
With new drugs targeting second-line therapy, a crowded treatment algorithm may be on the horizon for patients with NSCLC. 
With new drugs targeting...
02/02/2016
First Report Managed Care
02/02/2016
Eileen Koutnik-Fotopoulos
Eileen Koutnik-Fotopoulos
Payer clients are faced with alarmingly high-cost specialty drug trends with no clear direction on how to balance the dilemma of therapy versus cost. Add the explosive development of new specialty drugs over the next few years and payers...
Payer clients are faced with alarmingly high-cost specialty drug trends with no clear direction on how to balance the dilemma of therapy versus cost. Add the explosive development of new specialty drugs over the next few years and payers...
Payer clients are faced with...
02/02/2016
First Report Managed Care
02/02/2016

Eileen Koutnik-Fotopolous

Eileen Koutnik-Fotopolous
Now that the first biosimilar—filgrastim-sndz—has entered the US marketplace, policies and perceptions around these complex medicines are unfurling.
Now that the first biosimilar—filgrastim-sndz—has entered the US marketplace, policies and perceptions around these complex medicines are unfurling.
Now that the first...
02/02/2016
First Report Managed Care
02/02/2016
Dean Celia
Dean Celia
Drug costs are a top concern for voters, with polls showing that most are open to letting Medicare tackle the issue by negotiating drug prices. Here’s where the presidential candidates stand and what our experts believe are the potential...
Drug costs are a top concern for voters, with polls showing that most are open to letting Medicare tackle the issue by negotiating drug prices. Here’s where the presidential candidates stand and what our experts believe are the potential...
Drug costs are a top concern...
02/02/2016
First Report Managed Care
02/02/2016

Dean Celia

Dean Celia
The American Cancer Society's revised guidelines have inched closer to United States Preventive Services Task Force recommendations. How will this impact managed care? Our experts sort through the potential effect on Accountable Care...
The American Cancer Society's revised guidelines have inched closer to United States Preventive Services Task Force recommendations. How will this impact managed care? Our experts sort through the potential effect on Accountable Care...
The American Cancer...
02/02/2016
First Report Managed Care
02/02/2016

Jill Sederstrom

Jill Sederstrom
The momentum to establish accountable care organizations (ACOs) continues to grow, as both government and commercial payers make a push for providers to begin baring risk for patient populations. 
The momentum to establish accountable care organizations (ACOs) continues to grow, as both government and commercial payers make a push for providers to begin baring risk for patient populations. 
The momentum to establish...
02/02/2016
First Report Managed Care
02/02/2016

Paul Nicolaus

Paul Nicolaus
Is a fundamental structural issue with the exchange products overall to blame? Our experts think only time will tell. 
Is a fundamental structural issue with the exchange products overall to blame? Our experts think only time will tell. 
Is a fundamental structural...
02/02/2016
First Report Managed Care
02/02/2016

Jill Sederstrom

Jill Sederstrom
The percentage of MCOs using guidelines and pathways to direct cancer treatment is on the rise. 
The percentage of MCOs using guidelines and pathways to direct cancer treatment is on the rise. 
The percentage of MCOs using...
02/02/2016
First Report Managed Care

Advertisement

Advertisement

Advertisement